Active amines, specifically monoamine oxidase-B (MAO-B) inhibitors such as selegiline and rasagiline, are scientifically validated for use in the management of Parkinson's disease. These compounds work by inhibiting the MAO-B enzyme, which is responsible for the breakdown of dopamine in the brain. By reducing dopamine breakdown, these drugs help maintain higher levels of dopamine, alleviating some of the motor symptoms characteristic of Parkinson's disease, such as bradykinesia, rigidity, and tremor.

Multiple randomized controlled trials and meta-analyses have demonstrated that MAO-B inhibitors can provide symptomatic relief and may modestly slow the progression of disability in early Parkinson's disease, especially before levodopa therapy is initiated. For example, a meta-analysis in The Lancet Neurology (2015) confirmed the efficacy of rasagiline and selegiline in improving Unified Parkinson's Disease Rating Scale (UPDRS) scores. These agents are often used as adjunctive therapy to levodopa or as monotherapy in early disease stages.

Common side effects include insomnia, nausea, and, rarely, hypertensive reactions. Their use is based on well-established neurochemical principles and robust clinical trial evidence, reflected in major treatment guidelines. Thus, the use of active amines as MAO-B inhibitors in Parkinson's disease is well supported by scientific evidence.